“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study

This study aimed to evaluate the efficacy and safety of “highly exposed Chinese herbal medicine” combined with apatinib as maintenance treatment following first-line or second-line chemotherapy in patients with ES-SCLC. A total of 23 patients with ES-SCLC were included in this single-arm prospective...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mingqi Wang, Haili Jiang, Mei Zhang, Yang Chen, Ting Wang, Ping Li
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/e1faa1d7629d4d609098e93b5c4884eb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e1faa1d7629d4d609098e93b5c4884eb
record_format	dspace
spelling	oai:doaj.org-article:e1faa1d7629d4d609098e93b5c4884eb2021-11-13T23:03:19Z“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study1559-325810.1177/15593258211055016https://doaj.org/article/e1faa1d7629d4d609098e93b5c4884eb2021-10-01T00:00:00Zhttps://doi.org/10.1177/15593258211055016https://doaj.org/toc/1559-3258This study aimed to evaluate the efficacy and safety of “highly exposed Chinese herbal medicine” combined with apatinib as maintenance treatment following first-line or second-line chemotherapy in patients with ES-SCLC. A total of 23 patients with ES-SCLC were included in this single-arm prospective study (ChiCTR2100045255). “Highly exposed Chinese herbal medicine” combined with apatinib was administered each day after the chemotherapy for maintenance treatment. The primary endpoint of the study was median PFS, while the secondary endpoints included median OS, DCR, ORR, AE, and the association of “highly exposed Chinese herbal medicine” with PFS and OS. Three and 16 patients achieved partial response (PR) and stable disease (SD), respectively, and four patients were with disease progression (PD). The ORR of the patients was 13.0%, DCR was 83.0%, median PFS was 5.0 months, and median OS was 18.0 months. The major AE included secondary hypertension and hand-foot syndrome. Oral intake of Chinese herbal medicine for ≥ 6 months was associated with longer PFS. Hand-foot syndrome was an independent predictive factor for PFS. The statistical analysis suggested no independent influencing factors for OS. “Highly exposed Chinese herbal medicine” combined with apatinib is effective and relatively safe as the maintenance treatment for ES-SCLC patients who undergo first-line or second-line chemotherapy.Mingqi WangHaili JiangMei ZhangYang ChenTing WangPing LiSAGE PublishingarticleTherapeutics. PharmacologyRM1-950ENDose-Response, Vol 19 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Mingqi Wang Haili Jiang Mei Zhang Yang Chen Ting Wang Ping Li “Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
description	This study aimed to evaluate the efficacy and safety of “highly exposed Chinese herbal medicine” combined with apatinib as maintenance treatment following first-line or second-line chemotherapy in patients with ES-SCLC. A total of 23 patients with ES-SCLC were included in this single-arm prospective study (ChiCTR2100045255). “Highly exposed Chinese herbal medicine” combined with apatinib was administered each day after the chemotherapy for maintenance treatment. The primary endpoint of the study was median PFS, while the secondary endpoints included median OS, DCR, ORR, AE, and the association of “highly exposed Chinese herbal medicine” with PFS and OS. Three and 16 patients achieved partial response (PR) and stable disease (SD), respectively, and four patients were with disease progression (PD). The ORR of the patients was 13.0%, DCR was 83.0%, median PFS was 5.0 months, and median OS was 18.0 months. The major AE included secondary hypertension and hand-foot syndrome. Oral intake of Chinese herbal medicine for ≥ 6 months was associated with longer PFS. Hand-foot syndrome was an independent predictive factor for PFS. The statistical analysis suggested no independent influencing factors for OS. “Highly exposed Chinese herbal medicine” combined with apatinib is effective and relatively safe as the maintenance treatment for ES-SCLC patients who undergo first-line or second-line chemotherapy.
format	article
author	Mingqi Wang Haili Jiang Mei Zhang Yang Chen Ting Wang Ping Li
author_facet	Mingqi Wang Haili Jiang Mei Zhang Yang Chen Ting Wang Ping Li
author_sort	Mingqi Wang
title	“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
title_short	“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
title_full	“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
title_fullStr	“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
title_full_unstemmed	“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
title_sort	“highly exposed chinese herbal medicine” combined with apatinib as maintenance treatment following first-line or second-line chemotherapy for extensive-stage small-cell lung cancer: a single-arm, prospective study
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/e1faa1d7629d4d609098e93b5c4884eb
work_keys_str_mv	AT mingqiwang highlyexposedchineseherbalmedicinecombinedwithapatinibasmaintenancetreatmentfollowingfirstlineorsecondlinechemotherapyforextensivestagesmallcelllungcancerasinglearmprospectivestudy AT hailijiang highlyexposedchineseherbalmedicinecombinedwithapatinibasmaintenancetreatmentfollowingfirstlineorsecondlinechemotherapyforextensivestagesmallcelllungcancerasinglearmprospectivestudy AT meizhang highlyexposedchineseherbalmedicinecombinedwithapatinibasmaintenancetreatmentfollowingfirstlineorsecondlinechemotherapyforextensivestagesmallcelllungcancerasinglearmprospectivestudy AT yangchen highlyexposedchineseherbalmedicinecombinedwithapatinibasmaintenancetreatmentfollowingfirstlineorsecondlinechemotherapyforextensivestagesmallcelllungcancerasinglearmprospectivestudy AT tingwang highlyexposedchineseherbalmedicinecombinedwithapatinibasmaintenancetreatmentfollowingfirstlineorsecondlinechemotherapyforextensivestagesmallcelllungcancerasinglearmprospectivestudy AT pingli highlyexposedchineseherbalmedicinecombinedwithapatinibasmaintenancetreatmentfollowingfirstlineorsecondlinechemotherapyforextensivestagesmallcelllungcancerasinglearmprospectivestudy
_version_	1718430108808642560

“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study

Ejemplares similares